ZVSA
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.22 | $0 | -$799M |
| 2025 Q4 | -0.08 | $0 | -$414M |
| 2025 Q3 | -2.56 | $0 | -$1.4B |
| 2025 Q2 | -0.46 | $0 | -$2M |
| 2025 Q1 | -0.73 | $0 | -$1.8B |
| 2024 Q4 | -1.31 | $26,078 | -$1M |
| 2024 Q3 | -2.43 | $0 | -$3.1B |
| 2024 Q2 | -3.31 | $0 | -$2M |